TrialBlood2024

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.

Mendel Goldfinger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.